-
Jefferies Downgrades Mereo BipPharma Group (MREO) to Hold
-
Ultragenyx Pharma (RARE) PT Lowered to $70 at Leerink Partners
-
Mereo BipPharma Group (MREO) PT Lowered to $2 at Leerink Partners
-
Mereo BipPharma Group (MREO) PT Lowered to $1 at BTIG
-
LifeSci Capital Downgrades Mereo BipPharma Group (MREO) to Market Perform
-
Ultragenyx Pharma (RARE) PT Lowered to $47 at Baird
-
Mereo BipPharma Group (MREO) PT Lowered to $1 at Baird
-
Ultragenyx Pharma (RARE) PT Lowered to $50 (from $103) at Citi
-
William Blair Reiterates Outperform Rating on Ultragenyx Pharma (RARE)
-
Leerink Partners Reiterates Outperform Rating on Ultragenyx Pharma (RARE)
-
Mereo BioPharma (MREO) halted, news pending
-
Increasing unusual call option volume: XP YANG AMLP LW HNRG CWAN NXDR HTGC RSI
-
BTIG Reiterates Buy Rating on Mereo BipPharma Group (MREO)
-
Baird Names Mereo BipPharma Group (MREO) a New Fresh Pick into Clinical Data
-
ashibio licenses vantictumab from Mereo for rare bone disorder treatment
-
Mereo BioPharma (MREO) Misses Q2 EPS by 2c
-
BTIG Reiterates Buy Rating on Mereo BipPharma Group (MREO)
-
Mereo BipPharma Group (MREO) PT Lowered to $5 at Needham
-
JPMorgan Reiterates Overweight Rating on Mereo BipPharma Group (MREO)
-
Ultragenyx and Mereo advance UX143 osteogenesis imperfecta study to final analysis
-
Mereo BioPharma Group plc (MREO) Misses Q1 EPS by 3c
-
Cantor Fitzgerald Reiterates Overweight Rating on Mereo BipPharma Group (MREO)
-
JPMorgan Starts Mereo BipPharma Group (MREO) at Overweight
-
BTIG Reiterates Buy Rating on Mereo BipPharma Group (MREO)
-
Mereo and Ultragenyx remain top picks at Cantor Fitzgerald
-
Cantor Fitzgerald Reiterates Overweight Rating on Mereo BipPharma Group (MREO)
-
Increasing unusual call option volume: COMM INFY XLI JACK MREO UMC MRVI BIRK ARVN
-
Jefferies Starts Mereo BipPharma Group (MREO) at Buy
-
Mereo BioPharma (MREO) Files for 26.64M Share Offering by Selling Stockholders
-
Mereo BioPharma Group plc (MREO) Reports In-Line Q3 EPS
-
Baird Reiterates Outperform Rating on Mereo BipPharma Group (MREO)
-
Mereo BioPharma Group plc (MREO) Misses Q2 EPS by 1c
-
Mereo BioPharma (MREO) Prices 12.53M Share Offering at $3.99/sh
-
Baird Starts Mereo BipPharma Group (MREO) at Outperform
-
Ultragenyx Pharma (RARE), Mereo BioPharma (MREO) Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) i
-
Mereo BipPharma Group (MREO) PT Raised to $7 at Needham

